Retrospective Natural History Study of LAMA2 in Infants and Toddlers (LAMA2 rTNHS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04299321|
Recruitment Status : Not yet recruiting
First Posted : March 6, 2020
Last Update Posted : March 11, 2020
|Condition or disease|
|Merosin Deficient Congenital Muscular Dystrophy|
LAMA2-related congenital muscular dystrophy (LAMA2-CMD) is caused by a deficiency of the α2 subunit of laminin due to mutation of the LAMA2 gene.
Typical LAMA2-CMD cases present with prominent hypotonia and weakness in infancy. Congenital contractures are a common finding in the hands and feet. Weakness and contractures are slowly progressive, and most patients do not achieve independent ambulation. Facial weakness and jaw contractures disrupt normal feeding, resulting in failure to thrive. Most patients require nutrition support at an early age. Cardiac involvement is rare. In addition to neuromuscular aspects of the disorder, patients with LAMA2-CMD have central nervous system findings including prominent T2 and fluid-attenuated inversion recovery (FLAIR) abnormalities in the white matter on brain MRI. Despite the prominent changes on MRI, cognitive function is normal, although patients are at risk of seizures, which are seen in 30% of patients.
A number of potential therapies are currently in development for LAMA2-CMD. A larger prospective natural history was conducted at the National Institutes of Health in LAMA2-CMD patients, ages 5-16 years of age, testing and validating a wide variety of outcome measures suitable for use in clinical trials. However, appropriate clinical outcome measures in younger patients (ages 0-5 years) have yet to be validated.
Some treatments currently in development will almost certainly be more effective the earlier the treatment is administered. Given that there is a distinct lack of data for affected individuals less than 6 years of age, this study will be instrumental in building outcome measures appropriate in younger patients. In order to obtain regulatory authorization to launch clinical trials in affected individuals less than 6 years of age, a documented natural history for this age group must be demonstrated.
The primary objective of this study is to characterize aspects of LAMA2-CMD in ages 0-5 years through medical chart review/data extraction, and participant survey. This study aims to derive clinical trial endpoints useful in conducting interventional trials in the near future.
The secondary objectives of this study include identifying potential prognostic variables of LAMA2-CMD, identifying adverse events associated with LAMA2-CMD that warrant monitoring and potential preventative measures, and to grow the knowledge base of care standards and optimization to improve the patient's quality of life.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||LAMA2 Retrospective Review of Medical Charts in Infants & Toddlers With LAMA2-CMD|
|Estimated Study Start Date :||March 23, 2020|
|Estimated Primary Completion Date :||March 23, 2021|
|Estimated Study Completion Date :||June 30, 2021|
- To characterize the natural history of LAMA2-CMD [ Time Frame: Birth to 5 years of age ]To characterize aspects of LAMA2-CMD in ages 0-5 years through medical chart review/data extraction, and participant survey. This study aims to derive clinical trial endpoints useful in conducting interventional trials in the near future.
- To identify potential prognostic variables of LAMA2-CMD [ Time Frame: Birth to 5 years of age ]Overall analysis
- To identify adverse events associated with LAMA2-CMD that warrant monitoring and potential preventative measures [ Time Frame: Birth to 5 years of age ]Overall analysis
- To grow the knowledge base of care standards and optimization to improve the patient's quality of life [ Time Frame: Birth to 5 years of age ]Overall analysis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04299321
|Contact: Justin Park, BS||(562) 444-5656 ext email@example.com|
|Contact: Rachel Alvarez, BS||(562) 444-5656 ext firstname.lastname@example.org|
|Study Director:||Carsten Bönnemann, MD||NINDS/NIH|
|Study Director:||Reghan Foley, MD||NINDS/NIH|
|Study Director:||Oscar H Mayer, MD||Children's Hospital of Philadelphia|
|Study Director:||Alan Beggs, PhD||Boston Children’s Hospital|
|Study Chair:||Justin Park, BS||Cure CMD|
|Principal Investigator:||Gustavo Dziewczapolski, PhD||Cure CMD|
|Study Director:||Rachel Alvarez, BS||Cure CMD|